BIO

  • Sam Patrick posted an article
    BIO global CEO Jim Greenwood, Over 50 National Speakers to Present at SCBIO 2018 see more

    Conference registrations soar with sell-out expected; CEOs and top industry leaders head to Charleston for strategic partnership development, industry insights

     

    SOUTH CAROLINA – September 26, 2018BIO global CEO Jim Greenwood will join more than 50 additional national speakers at SCBIO 2018 – the annual conference bringing top leaders and executives from life sciences organizations across the state and nation to Charleston, South Carolina October 23-25.

    Mr. Greenwood will address the gathering with a keynote presentation entitled “Global Perspectives for Life Sciences – Compelling Opportunity for South Carolina” the morning of the conference opening on October 24.  His presentation will be bracketed by two high-powered panel discussions – a feature panel comprised of top pharmaceutical executives entitled “Pharma’s Future in the Palmetto State and Beyond,” and followed by the Southeast US Economic Development Luncheon featuring an address by Secretary of Commerce Bobby Hitt.  The luncheon will be capped by a panel featuring life sciences economic development CEOs from across the Southeastern region.  Conference Chair and Womble Bond Dickinson partner Stephanie Yarbrough will moderate the luncheon panel.

    Scores of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, clinicians and researchers, and industry supporters from across America have already registered to attend SCBIO 2018 at Charleston’s Gaillard Auditorium, with registration already doubling the pace of 2017.  Among committed speakers and panelists are DePuy Synthes Global Orthopedic Leader I.V. Hall, Nephron Pharmaceuticals CEO Lou Kennedy, J.P. Morgan Executive Director of Healthcare Investment Banking Bell Zhong, MUSC President David Cole, USC President Harris Pastides, Siemens Healthineers North Americas President Dave Pacitti, and numerous others.

    Themed “Connect.  Collaborate.  Advance!” the 2+ day conference draws attendees from across America for networking, innovation updates, opportunity discovery, partnership making and strategic discussion.  Committed attendees include officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio ag  and more.  Space is limited and advance registration is still available at https://www.scbio.org/events/scbio-annual-conference.

    SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products. 

    SCBIO 2018 kicks off Tuesday evening October 23 with an Opening Reception for conference registrants, speakers and sponsors at The Dewberry Hotel, presented by Explore Charleston and The Dewberry.  Wednesday will feature a complete day of sessions beginning at breakfast and continuing through a gala evening reception presented by Womble Bond Dickinson.  The conference will wrap up Thursday at lunchtime. 

    “The life sciences industry is a major driver of South Carolina’s economy, and this conference is testament to the industry’s growing impact, reach and rapidly rising economic significance in our state and region,” noted SCBIO President and CEO Sam Konduros. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, this sector has tremendous growth potential, and we’re excited to showcase the top companies, research universities and leaders from across our state and country at SCBIO 2018.” 

    Among leading biotech and med-tech industry brands participating in the conference are Nephron Pharmaceutical, BIO, Johnson & Johnson, AVX, PhRMA, DePuy Synthes, Medpoint, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, SoftBox Systems, ZEUS, Patheon Thermo Fisher and more.  All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are represented, as are major healthcare systems, and economic development entities including the South Carolina Department of Commerce, SCRA, the Upstate SC Alliance, the Charleston Regional Development Alliance, Central Carolina Alliance and SiMT.

    As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – SCBIO members include hundreds of academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.

  • Sam Patrick posted an article
    U.S. bioscience industry has reached $2 trillion in annual economic impact while continuing to grow see more

    Boston, MA (June 5, 2018) –  A study released today at the BIO International Convention shows that the U.S. bioscience industry has reached $2 trillion in annual economic impact while maintaining accelerated venture capital investment and job growth numbers. Among U.S. technology sectors, the bioscience industry has held a leading position as an economic driver and job generator.

    The report, Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry 2018, finds U.S. bioscience firms directly employ 1.74 million people, a figure that includes more than 273,000 high-paying jobs created since 2001. The average annual wage for a U.S. bioscience worker reached $98,961 in 2016. These earnings are more than $45,000 greater, on average, than the overall U.S. private sector wage. The report further shows that since 2014, the bioscience industry has grown by 4.4 percent with four of its five major subsectors contributing to this overall job gain.

    For the first time, the biennial report includes a full assessment of the economic impact of the bioscience industry and finds its total economic impact on the U.S. economy, as measured by overall output, totaled $2 trillion in 2016. This impact is generated by the direct output of the bioscience industry combined with the indirect (supply chain) and induced (employee spending) impacts. The industry and its associated economic output support 8 million jobs throughout the entire U.S. economy through both indirect and induced effects.

    “This report highlights the enormous economic impact delivered by our industry. This strong performance is due to the vital and wide-ranging collaborations between industry partners, universities, and policymakers that provides a business climate that supports the development of innovative bioscience products and high paying jobs,” said Jim Greenwood, President and CEO of the Biotechnology Innovation Organization."

    The report also takes the pulse of the broader U.S. innovation ecosystem for bioscience companies and finds it advancing with positive results. The U.S. is experiencing strong gains in bioscience venture capital funding, growth in patents, a recent ramp-up in bioscience-related university R&D expenditures and increasing research funding from the National Institutes of Health (NIH).

    “The bioscience industry is vital to the U.S. not only as an innovation engine that is improving lives, but also as a major economic driver that is consistently generating high-quality jobs and significant economic output across the nation,” said Ryan Helwig, Principal and Project Director with TEConomy Partners.

    The state-by-state industry assessment is the eighth in a biennial series, developed in partnership by TEConomy and BIO, presenting data on national, state, and metropolitan area bioscience industry employment and recent trends.

    Additional highlights from the industry economic analysis include:

    • The industry is a major economic driver and is well distributed across U.S. states and cities:
      • 41 states experienced net job growth in the biosciences between 2014-2016
      • 38 states and Puerto Rico have an employment specialization in at least one bioscience subsector
      • 213 of 383 U.S. metropolitan areas have at least one bioscience specialization

    Highlights from the analysis of the innovation ecosystem for the bioscience industry include:

    • Strength in recent venture capital and patenting trends:
      • Venture capital investments have reached new highs. More than $66 billion in venture capital was invested in bioscience companies during the 2014 through 2017 period, including a new annual high in 2017 at $20 billion invested.
      • Innovation continues to drive the biosciences, since 2014 the U.S. has increased patent totals in bioscience-related technology classes by nearly 5 percent, or 1.6 percent per year, on average. 2017 had a total of nearly 27,000 patents awarded to U.S. inventors, another new high.
    • Growth for academic biosciences R&D in 2016
      • After several years of concerns raised about the declining and/or flat NIH research budgets and the subsequent effects on academic and other research, NIH funding is back on the rise. There have been budget increases sustained each of the last three years.
      • Across America’s colleges and universities, the pace of R&D spending in bioscience-related research areas has increased. Following a 1.5 percent decline in 2015, academic R&D expenditures in the biosciences increased 5.5 percent to $42 billion in 2016.

  • Sam Patrick posted an article
    South Carolina Innovators, Inventors convene at SEMDA conference to present to Venture Capitalists see more

    State’s Innovators, Inventors, convene at conference to present to Venture Capitalists

     

    GREENVILLE, SC – April 6, 2018 – The Southeastern Medical Device Association (SEMDA) -- a non-profit trade association driven to make the southeast a world-class region for medical technology, device, and diagnostic companies – brings its 2018 conference to South Carolina for the first time May 2-4, 2018, attracting hundreds of executives to Greenville to meet, negotiate, learn, network and grow the medical device industry in the Southeast.

    Focused on accelerating device development and helping organizations and individuals gain access to funding, education, and networking opportunities, the annual conference is a must-attend for medical device companies, inventors, physicians, investors, tech transfer offices, universities, and service providers interested in growing the medical device industry in North America, and even globally.

    As part of SEMDA 2018’s many activities, SCBIO and SCRA are collaborating to present PitchRounds 2018 – a highly targeted venue for both start-ups and “Seed” companies as well as later-stage (or Series A or later) organizations to present their ideas, innovations and products to panels of institutional investors, regulatory leaders, venture capital directors, IP experts and others in structured sessions. 

    Selected participants will receive individual feedback on their presentations and compete for $10,000 in top prize money for selected winners.  Participating presenters also receive two full conference registrations and access to meet with investors and partners at sessions and networking receptions.  Global law firm Eversheds Sutherland, one of the 50 largest law firms globally, is also a co-sponsor of PitchRounds.

    Applying to present is both free and simple, with full details available online at www.SEMDA.net/conference/pitchrounds or at www.SCBIO.org.  The deadline to complete the simple application to be considered is close of business April 13, 2018.

    SCBIO Vice President Erin Ford noted, “SCBIO and our co-sponsors are delighted to make PitchRounds a possibility for South Carolina’s emerging medtech companies to showcase their innovations and solutions, and to directly access investors and industry leaders to gain direct feedback on their innovations.”

    “While entries will be considered from across the entire Southeast and presentation spots are limited, we are confident that South Carolina will be well represented based on the robust pipeline of innovations the South Carolina life sciences community has been working on.  We encourage all early- and later-stage companies to enter the PitchRounds program and showcase the Palmetto State’s talents.”

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms and 15,000 professionals directly involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.

  • Sam Patrick posted an article
    BIO International Convention, the world’s premier life sciences event, returns to Boston June 4-7 see more

    The BIO International Convention, the world’s premier life sciences event, will return to the Boston Convention & Exhibition Center June 4-7, to celebrate 25 years of advocacy and innovation. The 2018 event is expected to attract more than 16,000 attendees and 1,800 exhibitors from 74 countries – including an SCBIO-led delegation of 20+ from South Carolina --all who will be welcomed in a special, keynote address by ABC’s Robin Roberts.  Read on for full details...

  • Sam Patrick posted an article
    SCBIO celebrates the accomplishments of all women in life sciences on International Women's Day... see more

    In honor of International Women’s Day, BIO and SCBIO are celebrating the accomplishments of all women making a difference in the life sciences industry, and highlighting the work of two leaders and pioneers in healthcare—Sue Desmond-Hellmann, CEO of the Bill & Melinda Gates Foundation, and Penny Heaton, CEO of the Bill & Melinda Gates Medical Research Institute (Gates MRI).

    At a fireside chat during the upcoming BIO 2018 (which SCBIO will be attending in force), Desmond-Hellmann and Heaton will lead a discussion about the mission and vision for the Gates MRI. As leaders in science and business, they have been instrumental in advancing medical breakthroughs and are champions for issues that affect women around the world.  Read on for full details.

  • Sam Patrick posted an article
    SCBIO has named its 2018 Board of Directors and Board Chair see more

    SCBIO has announced its 2018 Board of Directors and Executive Committee following formal confirmation at the life science organization’s December 2017 meeting in Columbia.  Nephron Pharmaceuticals Corporation CEO Lou Kennedy will serve as SCBIO’s 2018 Board Chair.

    Ms. Kennedy joined Nephron Pharmaceuticals in 2001, and assumed the position of President and CEO in 2007. She has held a variety of marketing and operational roles during her career and has helped Nephron Pharmaceuticals grow by 300% and increased shipped product to one billion doses each of the last seven years.  Nephron recently built a state of the art manufacturing facility in West Columbia, South Carolina and, with her husband Bill, helped establish the Kennedy Pharmacy Innovation Center in conjunction with the USC School of Pharmacy.

    Joining Ms. Kennedy as officers on the SCBIO Executive Committee will be Craig Walker, CEO of VidiStar LLC as Vice Chair; Michael Rusnak, Executive Director of the Medical University of South Carolina Research Foundation as Treasurer; and Kathryn Cole Becker, Principal of Translational Science Solutions as Secretary.  Additional members of the Executive Committee are Jeff Stover, Special Counsel with Haynsworth Sinkler Boyd, PA as Legal Officer; Stephanie Yarbrough, Partner with Womble Bond Dickinson, LLP as Annual Conference Officer; Bryan Davis, Operations Manager with Greenville Health System’s Office of Innovations as Healthcare/Innovation Officer; and Sam Konduros, President and CEO of SCBIO.  Immediate Past Chair, Erin Ford, who now serves as the organization’s inaugural Vice President, was honored for her extraordinary board service during the December Board meeting.

    Also elected to the 22-member Board of Directors for SCBIO are Darralyn Alexander, President of Reimbursement Strategies LLC; Mandy Brawley, Deputy Director of the South Carolina Department of Commerce; Jerry Chang, Vice President of Business Development for BioD; Matthew Couvillion, Attorney with the Wyche Law Form; J.J. Darby, State Government Affairs Leader for Johnson & Johnson Services; Tressa Gardner, Associate Vice president of the Southeastern Institute of Manufacturing and Technology at Florence-Darlington Technical College; and Mike Graney, Vice President  for Global Business Development of the Charleston Regional Development Alliance.

    Completing the 2018 Board of Directors for SCBIO are Chad Hardaway, Associate Director of the Office of Economic Engagement at the University of South Carolina; Willard Harms, VP of Medical Affairs for Blue Cross Blue Shield of South Carolina; Dr. Martine LaBerge, Chair of Clemson University’s Department of Bioengineering; Marc Metcalf, Business Recruitment Officer of the Upstate SC Alliance; Kathy Phlegar, President of Phlegar & Associates; Christine Dixon Thiesing, Director of Academic Programs for the South Carolina Research Authority; and Courtney Warren, Life Sciences Practice Chair for Marsh & McLennan Agency.

    SCBIO President and CEO Konduros praised the Board and Executive Committee noting, “With the important work we are undertaking to actively advance life sciences R&D, biotech, med-tech, and digital health industries in South Carolina, we require strong, expert leadership from all across the state, fully integrating the business, education and economic development sectors. I am confident that these diverse leaders who reside in communities ranging from Murrells Inlet to Florence in addition to Greenville, Columbia, and Charleston, will effectively champion our vision of building the business of life sciences in South Carolina in 2018 and for years to come.”

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry already has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.

    The Board of Directors is the policy- and strategy-making body of the organization, and meets regularly to receive updates on SCBIO business and objectives, as well as domestic and global initiatives. The Executive Committee serves roles specific to SCBIO operations, focus areas and strategies.

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.